# From success story to cautionary tale: Assessing Japan's vaccination effort

27 May 2021

### By Naoki Kamiyama, Chief Strategist

### Introduction

Until recently, Japan was lauded as one of the few countries that successfully limited the COVID-19 outbreak. However, more than a year into the pandemic, Japan's slow vaccine rollout is coming under increased scrutiny with the country lagging far behind its G7 peers in vaccinations. We explain the reasons behind the sluggish rollout, review the prospects for inoculation gathering speed, analyse the potential impact of the summer Olympic games being held at a delicate time for the country and assess the prospects for the economy, political situation and markets post-vaccination.

# Japan's healthcare system: Universal but fragile in crisis

### Japan's still low infection rate less of a comfort in second year of pandemic

Before looking at Japan's vaccination rollout, it's worth examining the country's healthcare system and why the still relatively limited number of infections is less of a comfort with the pandemic in its second year.


The main feature of Japan's healthcare system is that all residents, in theory, are eligible to receive medical care through a universal healthcare plan. This has resulted in easy access to healthcare: most residents would not think twice before visiting the doctor, even at the slightest hint of a cold. Providing Japan's large population with habitual access to healthcare is a vast number of small-scale private clinics and hospitals that can be found in any neighbourhood. These institutions are ill-equipped to deal with a pandemic. In contrast, large, public hospitals with the staff and equipment necessary to handle an outbreak are few and far between. This means that the entire healthcare system, despite the large number of registered medical personnel and hospital beds, is quickly stretched to the limit during national emergencies such as a pandemic.

With such a fragile healthcare system, the only option available to the government is to limit economic activity in the hopes of controlling the movement of people and thus the number of infections, even if the number of severely ill COVID-19 patients is relatively low. Speeding up the vaccine rollout is therefore of paramount importance both from a medical and economic view.





Chart 1: New COVID-19 cases per million people



Source: Our World in Data, as at 27 May 2021

### Why Japan's vaccination efforts have lagged

We can identify two main reasons for Japan's slow rollout. First, Japan has so far been unable to develop its own vaccine and is therefore reliant on imports; in other words, it essentially needs to wait until vaccine-producing countries are first done inoculating their own populations. Japan is home to some pharmaceutical companies with the potential ability to develop COVID-19 vaccines. However, the government, unlike its peers in countries such as the US, failed to swiftly provide Japanese pharmaceutical companies with the incentives for speedy vaccine development.

Second, Japan has a particularly onerous approval process for pharmaceuticals—developed because of numerous drug disasters in the past—which considerably slows the development and import of vaccines. For example, Japan, where only the Pfizer coronavirus vaccine had been approved, did not give the green light to the Moderna and AstraZeneca vaccines until 20 May as the authorities conducted trials in Japan to evaluate their efficacy and safety. Furthermore, stringent regulations mean that, until recently, only nurses and doctors were able to administer vaccines.



**■**Japan 70 -US 60 UK Germany India Israel 30 20 10 1-Mar-2021 1-Feb-2021 1-Apr-2021 1-Jan-2021 1-May-2021

Chart 2: Percentage of population receiving at least one dose of COVID-19 vaccine

Source: Our World in Data, as at 27 May 2021

## Vaccinating the elderly key to re-opening the economy

### Japan aims to inoculate those 65 years or older by end-July

The government's plan is to prioritise the inoculation of those aged 65 or older, representing 36 million people, or 30%, of the population of 126 million. The inoculation of the elderly began on 12 April and the government aims to vaccinate the entire age group, roughly equal in size to the population of Canada, by the end of July. While inoculations have gathered pace after a slow start, about a million shots still need to be administered daily for everyone in the age group to be fully vaccinated by the end of July. Despite the formidable task, 93% of local governments plan to vaccinate elderly within their constituencies by the target date, according to the media.

Following a sluggish start, vaccination in Japan is finally gaining momentum (Chart 3). State-run mass vaccination centres were opened in Tokyo and Osaka, Japan's two largest cities, on 24 May, with the government recruiting the country's military to operate the venues. Local governments in other areas are also planning to set up their own mass vaccination sites, with baseball stadiums being considered as potential venues. Stringent regulations are also being softened so Japan can deal with a shortage of eligible medical staff. Japan recently allowed dentists to administer COVID-19 vaccines, and, according to local media, the government is considering adding clinical laboratory technicians and paramedics to the list of eligible medical professionals.






Chart 3: Total number of vaccine doses administered in Japan

Source: Office of the Prime Minister and the Cabinet, as at 27 May 2021

Inoculation of the elderly will significantly alleviate the strains currently placed on Japan's medical system. For a country such as Japan with a sizable percentage of older citizens, vaccinating a large segment of the population most at risk of severe illness caused by COVID-19 will allow the government to ease economic restrictions even if overall infection rates remain relatively high. Once the elderly are inoculated, the government will not have to wait until a large majority of the population, such as 80%, is vaccinated before easing economic restrictions.

### Elections to come into focus once vaccinations gain traction

It will be in the best interests of current Prime Minister Yoshihide Suga to ease economic restrictions as soon as possible, in our view, as that would allow the premier to call a snap election for Japan's powerful House of Representatives¹ (lower house). Suga's term as president of the ruling Liberal Democratic Party (LDP), and thus his term as prime minister, expires at the end of September. The best-case scenario for Suga would be for him to dissolve the House of Representatives, quickly call a snap election and lead the LDP to a lower house victory before his term as LDP president runs out. That would put Suga on track to retain his position as party president when the LDP chooses its leader in September. We therefore need to view easing of COVID-19 restrictions and the normalisation of economic activity through the perspective of Japan's politics, as reducing the number of severely ill patients and freeing up hospital beds through vaccinations could shore up support for Suga, currently seeing a steady decline in public approval ratings, and pave the way for an early snap election.

<sup>&</sup>lt;sup>1</sup> The four-year term for members of the lower house expires on 22 October 2021, requiring the appointment of new-term members through a general election.

# From success story to cautionary tale: Assessing Japan's vaccination effort



### Dilemma for Japan as public support for the Olympics wanes

The summer Olympics and Paralympics to be hosted by Tokyo in July are also likely to impact political developments. If the vaccinations proceed as planned, the inoculation of the elderly should be almost completed by the time the games begin late in July. Regardless of how vaccinations proceed, the Olympics could still create a dilemma for the Suga administration. Many public polls currently show the majority of Japanese residents either opposed to hosting the games or in support of further postponement. If Japan goes ahead with the Olympics, Suga's already low approval rating could suffer even more—something he surely wants to avoid before the upcoming election.

It's also worth noting that if the government were to do an about-face and cancel its hosting of the Olympics, the impact on the economy and markets would likely be limited. While 90,000 athletes and related personnel are expected to come to Japan for the games, the number of foreign tourists visiting the country at the same time will be virtually zero. Inbound demand created by such a limited number of visitors is bound to be minimal.

### Conclusion

Instead of the Olympics, Japan will likely look to domestic demand to kick start its economy once a significant portion of its population is vaccinated. Vaccination and the subsequent normalization of economic activity will help revive sectors that were hit hardest by the pandemic, notably those related to travel (both business and leisure), tourism, lodging and food and beverages. The government backed "GoTo" campaign, which provides travellers and diners with discounts, should help get the economy back in shape by resuscitating these downtrodden sectors, in our view.

From a market perspective, the normalization of economic activity means a recovery in shares of companies that were given the value label during the pandemic, such as those linked to railways, airlines and hotels. Only when Japan is back on its feet with the help of measures such as the GoTo campaign can we turn our focus to post-pandemic economic trends such as decarbonization, which appears to have made progress helped by Suga's initiatives, but still likely faces many uncertainties before Japan can genuinely benefit from it.

# From success story to cautionary tale: Assessing Japan's vaccination effort



Important information: This document is prepared by Nikko Asset Management Co., Ltd. and/or its affiliates (Nikko AM) and is for distribution only under such circumstances as may be permitted by applicable laws. This document does not constitute personal investment advice or a personal recommendation and it does not consider in any way the objectives, financial situation or needs of any recipients. All recipients are recommended to consult with their independent tax, financial and legal advisers prior to any investment. This document is for information purposes only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any investments or participate in any trading strategy. Moreover, the information in this document will not affect Nikko AM's investment strategy in any way. The information and opinions in this document have been derived from or reached from sources believed in good faith to be reliable but have not been independently verified. Nikko AM makes no guarantee, representation or warranty, express or implied, and accepts no responsibility or liability for the accuracy or completeness of this document. No reliance should be placed on any assumptions, forecasts, projections, estimates or prospects contained within this document. This document should not be regarded by recipients as a substitute for the exercise of their own judgment. Opinions stated in this document may change without notice. In any investment, past performance is neither an indication nor guarantee of future performance and a loss of capital may occur. Estimates of future performance are based on assumptions that may not be realised. Investors should be able to withstand the loss of any principal investment. The mention of individual securities, sectors, regions or countries within this document does not imply a recommendation to buy or sell.

Nikko AM accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this document, provided that nothing herein excludes or restricts any liability of Nikko AM under applicable regulatory rules or requirements. All information contained in this document is solely for the attention and use of the intended recipients. Any use beyond that intended by Nikko AM is strictly prohibited.

**Japan**: The information contained in this document pertaining specifically to the investment products is not directed at persons in Japan nor is it intended for distribution to persons in Japan. Registration Number: Director of the Kanto Local Finance Bureau (Financial Instruments firms) No. 368 Member Associations: The Investment Trusts Association, Japan/Japan Investment Advisers Association.

**United Kingdom and rest of Europe**: This document is communicated by Nikko Asset Management Europe Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the FCA) (FRN 122084). This document constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 (as amended) (FSMA) and the rules of the FCA in the United Kingdom, and is directed at professional clients as defined in the FCA Handbook of Rules and Guidance.

**United States:** This document may not be duplicated, quoted, discussed or otherwise shared without prior consent. Any offering or distribution of a Fund in the United States may only be conducted via a licensed and registered broker-dealer or a duly qualified entity. Nikko Asset Management Americas, Inc. is a United States Registered Investment Adviser.

**Singapore**: This document is for information to institutional investors as defined in the Securities and Futures Act (Chapter 289), and intermediaries only. Nikko Asset Management Asia Limited (Co. Reg. No. 198202562H) is regulated by the Monetary Authority of Singapore.

**Hong Kong:** This document is for information to professional investors as defined in the Securities and Futures Ordinance, and intermediaries only. The contents of this document have not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong. Nikko Asset Management Hong Kong Limited is a licensed corporation in Hong Kong.

**New Zealand**: This document is issued in New Zealand by Nikko Asset Management New Zealand Limited (Company No. 606057, FSP22562). It is for the use of wholesale clients, researchers, licensed financial advisers and their authorised representatives only.

**Kingdom of Bahrain**: The document has not been approved by the Central Bank of Bahrain which takes no responsibility for its contents. No offer to the public to purchase the Strategy will be made in the Kingdom of Bahrain and this document is intended to be read by the addressee only and must not be passed to, issued to, or shown to the public generally.

**Kuwait**: This document is not for general circulation to the public in Kuwait. The Strategy has not been licensed for offering in Kuwait by the Kuwaiti Capital Markets Authority or any other relevant Kuwaiti government agency. The offering of the Strategy in Kuwait on the basis a private placement or public offering is, therefore, restricted in accordance with Decree Law No. 7 of 2010 and the bylaws thereto (as amended). No private or public offering of the Strategy is being made in Kuwait, and no agreement relating to the sale of the Strategy will be concluded in Kuwait. No marketing or solicitation or inducement activities are being used to offer or market the Strategy in Kuwait.

**Kingdom of Saudi Arabia**: This document is communicated by Nikko Asset Management Europe Ltd (Nikko AME), which is authorised and regulated by the Financial Services and Markets Act 2000 (as amended) (FSMA) and the rules of the Financial Conduct Authority (the FCA) in the United Kingdom (the FCA Rules). This document should not be reproduced, redistributed, or sent directly or indirectly to any other party or published in full or in part for any purpose whatsoever without a prior written permission from Nikko AME. This document does not constitute investment advice or a personal recommendation and does not consider in any way the suitability or appropriateness of the subject matter for the individual circumstances of any recipient. In providing a person with this document, Nikko AME is not treating that person as a client for the purposes of the FCA Rules other than those relating to financial promotion and that person will not therefore benefit from any protections that would be available to such clients. Nikko AME and its associates and/or its or their officers, directors or employees may have or have had positions or material interests, may at any time make purchases and/or sales as principal or agent, may provide or have provided corporate finance services to issuers or may provide or have provided significant advice or investment services in any investments referred to in this document or in related investments. Relevant confidential information, if any, known within any company in the Nikko AM group or Sumitomo Mitsui Trust Holdings group and not available to Nikko AME because of regulations or internal procedure is not reflected in this document. The investments mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors.

Oman: The information contained in this document nether constitutes a public offer of securities in the Sultanate of Oman as contemplated by the Commercial companies law of Oman (Royal decree 4/74) or the Capital Markets Law of Oman (Royal Decree80/98, nor does it constitute an offer to sell, or the solicitation of any offer to buy non-Omani securities in the Sultanate of Oman as contemplated by Article 139 of the Executive Regulations to the Capital Market law (issued by Decision No. 1/2009). This document is not intended to lead to the conclusion of any contract of whatsoever nature within the territory of the Sultanate of Oman.

**Qatar (excluding QFC):** The Strategies are only being offered to a limited number of investors who are willing and able to conduct an independent investigation of the risks involved in an investment in such Strategies. The document does not constitute an offer to the public and

# From success story to cautionary tale: Assessing Japan's vaccination effort nikko



should not be reproduced, redistributed, or sent directly or indirectly to any other party or published in full or in part for any purpose whatsoever without a prior written permission from Nikko Asset Management Europe Ltd (Nikko AME). No transaction will be concluded in your jurisdiction and any inquiries regarding the Strategies should be made to Nikko AME.

United Arab Emirates (excluding DIFC): This document and the information contained herein, do not constitute, and is not intended to constitute, a public offer of securities in the United Arab Emirates and accordingly should not be construed as such. The Strategy is only being offered to a limited number of investors in the UAE who are (a) willing and able to conduct an independent investigation of the risks involved in an investment in such Strategy, and (b) upon their specific request. The Strategy has not been approved by or licensed or registered with the UAE Central Bank, the Securities and Commodities Authority or any other relevant licensing authorities or governmental agencies in the UAE. This document is for the use of the named addressee only and should not be given or shown to any other person (other than employees, agents or consultants in connection with the addressee's consideration thereof). No transaction will be concluded in the UAE and any inquiries regarding the Strategy should be made to Nikko Asset Management Europe Ltd.

Republic of Korea: This document is being provided for general information purposes only, and shall not, and under no circumstances is, to be construed as, an offering of financial investment products or services. Nikko AM is not making any representation with respect to the eligibility of any person to acquire any financial investment product or service. The offering and sale of any financial investment product is subject to the applicable regulations of the Republic of Korea. Any interests in a fund or collective investment scheme shall be sold after such fund is registered under the private placement registration regime in accordance with the applicable regulations of the Republic of Korea, and the offering of such registered fund shall be conducted only through a locally licensed distributor.